Novel nucleic acid structure comprising RNA / DNA hybrid structure and use thereof
The introduction of an RNA/DNA hybrid structure at the 3' end of mRNA in nucleic acid constructs enhances protein expression and reduces immune responses, addressing stability and immune activation issues in mRNA-based therapeutics for vaccines and gene therapy.
Patent Information
- Application Number
- PCT/KR2024/006543
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current mRNA-based therapeutics face challenges in maintaining stability and minimizing immune responses, leading to reduced protein expression and potential inflammation, especially in chronic disease treatments requiring repeated administration.
A novel nucleic acid construct featuring an RNA/DNA hybrid structure at the 3' end of the mRNA, which includes an additional RNA sequence and a complementary DNA sequence forming a double strand, enhancing protein expression while suppressing excessive immune responses.
The RNA/DNA hybrid structure increases protein expression levels and reduces immune-inducing abilities, making it suitable for universal application in mRNA vaccines and gene therapy without chemical modification of mRNA.
Smart Images

Figure KR2024006543_21112024_PF_FP_ABST
Abstract
Description
Novel nucleic acid structure comprising RNA / DNA hybrid structure and use thereof The present invention relates to a novel nucleic acid structure having suppressed immune-inducing ability and enhanced protein expression level and its use, and more particularly, to an mRNA / DNA structure comprising a coding region encoding a target peptide or protein; and an RNA / DNA hybrid structure; and a pharmaceutical composition for a vaccine or gene therapy comprising the mRNA / DNA structure. Advances in science and technology in recent years have made mRNA a promising candidate for a new class of drugs. Sahin U. et al., Nat. Publ. Gr. 13, 759-780 (2014) provided an overview of mRNA-based therapeutics and drug development. mRNA is used to induce the in vivo production of proteins, such as antibodies and enzymes, or to stimulate immune responses by expressing specific epitopes or by inducing an innate immune response to structural mRNA fragments. The application of mRNA to stimulate immune responses could be used in novel approaches to treat cancer, AIDS, and develop vaccines for virtually any disease. Key to these developments lies the robust in vitro production of stabilized mRNA with enhanced translation efficiency and its delivery to cells using specific transfection agents. mRNA products produced using in vitro transcription (IVT) have recently attracted attention as a potential new drug class for vaccines or gene therapy. Because IVT mRNA functions directly in the cytosol without being transported to the nucleus, it can be engineered to transiently express proteins, similar to native mRNA. However, mRNA can be easily degraded by exonucleases (RNAses), which are commonly present both inside and outside cells. Furthermore, to function as a safe and effective RNA-based vaccine or therapeutic, it must provide sufficient expression of the target protein, both at the level and duration of expression, and provide minimal stimulation of the innate immune system to prevent inflammation and avoid specific immune responses in the target. It is known that mRNA degradation by exonuclease in the in vivo environment has a significant impact on protein expression. Therefore, when producing therapeutic mRNA, continuous efforts have been made in various fields to avoid degradation of the initial mRNA and ultimately improve mRNA stability. To date, attempts to increase the stability and protein expression levels of therapeutic mRNA preparations in vivo have focused on modification and selection of the untranslated region (UTR), nucleic acid variants (e.g., m1Ψ), and improvement of the cap structure. Despite the poly A tail located at the 3' end of the mRNA structure playing a crucial role in mRNA stability by exonuclease, research and development is insufficient except for research by Curevac and BioNTech, known as leading companies in the development of COVID-19 mRNA vaccines. While the unique immunostimulatory properties of therapeutic RNA may be considered desirable features of vaccines, these effects can lead to undesirable complications. This is particularly true for the treatment of chronic diseases that require repeated, long-term administration of RNA therapeutics. The potential ability of therapeutic RNA to elicit innate immune responses may limit its in vivo application. Under these technical backgrounds, the present inventors have made efforts to develop a nucleic acid structure platform that reduces excessive immunostimulatory properties of mRNA and increases the expression level of a target protein. As a result, they have confirmed that the platform exhibits reduced immunogenicity and increased protein expression rate without chemical modification of mRNA by introducing a hybrid structure containing additional RNA and complementary DNA to the poly A terminus of an mRNA structure that can be used in the fields of gene therapy and vaccines, thereby completing the present invention. The above information described in this background section is solely intended to enhance understanding of the background of the present invention and may not include information that constitutes prior art already known to a person of ordinary skill in the art to which the present invention pertains. The purpose of the present invention is to provide a novel nucleic acid structure that lowers immune-inducing ability and increases protein expression level. Another object of the present invention is to provide a pharmaceutical composition for a vaccine and a vaccine therapy comprising the nucleic acid structure. Another object of the present invention is to provide a pharmaceutical composition for gene therapy and a gene therapy method comprising the nucleic acid structure. Another object of the present invention is to provide a use of the nucleic acid structure for vaccine therapy and gene therapy and a use of the nucleic acid structure for the manufacture of a vaccine or gene therapy drug. In order to achieve the above object, the present invention provides an mRNA / DNA structure comprising a coding region (ORF) encoding a target peptide or protein; and an RNA / DNA hybrid structure linked to the 3' end of a poly A tail; wherein the RNA / DNA hybrid structure is characterized in that an additional RNA sequence and a DNA sequence complementary to the additional RNA sequence complementarily bind to form a double strand. The present invention also provides a vaccine or a pharmaceutical composition for gene therapy comprising the mRNA / DNA structure. The present invention also provides a vaccination or gene therapy method comprising a step of administering the mRNA / DNA construct. The present invention also provides the use of the mRNA / DNA construct for the manufacture of a vaccine or gene therapy. In the case of the mRNA / DNA structure platform according to the present invention, by introducing an RNA / DNA hybrid, excessive immune response due to mRNA is suppressed, and thus the protein expression rate is increased, so that it can be usefully and universally used in the fields of mRNA vaccines and gene therapy. Figure 1 is a schematic diagram of a novel mRNA / DNA nucleic acid structure in which an RNA / DNA hybrid structure is introduced at the 3' end of mRNA according to the present invention. Figure 2 shows the results of performing PCR using pDNA template for IVT mRNA synthesis, and electrophoresis using 1% agarose gel after purification. Figure 2a shows the results of using DNA vector (pUCIDT-AMP-DsRed Express2) containing T7 promoter, 5'UTR, open reading frame (ORF), and 3'UTR for IVT mRNA synthesis, Figure 2b shows the results of using DNA vector (Luciferase-pcDNA3) containing T7 promoter, 5'UTR, ORF, and 3'UTR, and Figure 2c shows the results of using DNA vector (pUC-pc-EPO) containing T7 promoter, 5'UTR, ORF, and 3'UTR as transcription templates. Figure 3 is a drawing showing the results of confirming the presence or absence of dsRNA using Dot-blot after performing cellulose purification to remove dsRNA, an impurity generated during the IVT mRNA synthesis process. Figure 4 is a drawing showing the production of a novel nucleic acid structure in which an RNA / DNA hybrid structure is introduced to the 3' end of mRNA through annealing, and confirmation that the RNA / DNA hybrid structure is well introduced. Figure 4a is the result of electrophoresis of a 15% PAGE gel, and Figure 4b is the result of Dot-blot using S9.6 antibody (Anti-DNA-RNA Hybrid antibody). Figure 5 is a graph showing the results of confirming the Firefly Luciferase protein expression ability of a novel nucleic acid construct in which an RNA / DNA hybrid structure is introduced at the 3' end of IVT mRNA and mRNA using 293T cells, and is a drawing showing excellent Firefly Luciferase protein expression ability in the mRNA / DNA novel nucleic acid construct regardless of the sequence or length of the RNA / DNA hybrid structure. FIG. 6 is a drawing showing the characteristics (Diameter Size, PDI, Encapsulation Efficiency%) of lipid nanoparticles (LNPs) encapsulated with IVT mRNA and a novel mRNA / DNA nucleic acid structure containing an RNA / DNA hybrid structure at the 3' end of the mRNA using a microfluidic device, NanoAssemblr® Ignite™ from Precision Nanosystems. FIG. 6a shows the result of encapsulating a nucleic acid structure encoding RFP (red fluorescent protein) into lipid nanoparticles, and FIG. 6b shows the result of encapsulating a nucleic acid structure encoding EPO (erythropoietin) into lipid nanoparticles. Figure 7 is a graph showing the results of confirming the RFP expression ability by time period (3, 6, 18, 24, 48 hours) after encapsulating an mRNA / DNA novel nucleic acid structure containing an RNA / DNA hybrid structure at the 3' end of IVT mRNA and mRNA into lipid nanoparticles (LNPs) using 293T cells (Figure 7a) and an AUC graph of the protein expression amount (Figure 7b). Figure 8 is a graph showing the results of confirming the RFP expression ability after inducing differentiation of human-derived THP-1 (monocyte cell line) into macrophages, and then encapsulating IVT mRNA and a novel mRNA / DNA nucleic acid structure containing an RNA / DNA hybrid structure at the 3' end of the mRNA into lipid nanoparticles (LNPs). Figure 9 is a graph (Figure 9a) and an AUC (Figure 9b) showing the EPO expression ability confirmed by ELISA after IVT mRNA and mRNA / DNA novel nucleic acid structures containing RNA / DNA hybrid structures at the 3' end were well wrapped with lipid nanoparticles (LNPs) and injected retro-orbitally into BALB / c mice and plasma was separated at time intervals (3 and 6 hours). Figure 10 shows the results of confirming the interferon (IFN) induction ability of IVT mRNA and mRNA / DNA novel nucleic acid constructs containing RNA / DNA hybrid structures at the 3' end of mRNA. Human THP-1 Dual™ cells (Invivogen) were used, and differentiation into macrophages was induced using PMA. Then, 200 ng of mRNA and mRNA / DNA novel nucleic acid constructs were transfected, and after 18 to 24 hours, 25 μl of the cell supernatant was used to confirm interferon (IFN) through the Quanti-Luc test. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein is well known and commonly used in the art. In one embodiment of the present invention, a platform capable of suppressing excessive immune responses induced by mRNA and exhibiting a higher protein expression rate than existing IVT mRNA was developed by using a novel mRNA / DNA structure including an RNA / DNA hybrid structure in which an RNA sequence additionally linked to the 3' end of the poly A tail of the mRNA structure and a DNA sequence complementary thereto are combined to form a double strand. Accordingly, the present invention relates to an mRNA / DNA structure comprising, in one aspect, a coding region (ORF) encoding a target peptide or protein; and an RNA / DNA hybrid structure linked to the 3' end of a poly A tail; wherein the RNA / DNA hybrid structure is characterized in that an additional RNA sequence and a DNA sequence complementary to the additional RNA sequence complementarily bind to form a double strand. In the present invention, the additional RNA sequence is any polyribonucleotide sequence or random RNA sequence linked to the 3' end of the poly A tail of the mRNA structure, and can be applied without limitation as long as it is a sequence that increases the protein expression rate of the mRNA structure without interfering with the UTR or ORF sequence. In the present invention, the additional RNA sequence may be an RNA sequence of any length, and may be characterized by including 5 to 100 nucleotides (nt), but is not limited thereto. Preferably, it may be characterized by including 10 to 80 nt, more preferably 15 to 60 nt, and most preferably 19 to 49 nt, but is not limited thereto. In the present invention, the DNA sequence can be applied without limitation as long as it is a sequence that can complementarily bind to an RNA sequence, including a sequence complementary to the additional RNA sequence. In the present invention, the DNA sequence may be characterized in that it further includes a poly T sequence complementary to a portion of the poly A sequence at the 3' end of the poly A tail, that is, the 3' end of the DNA sequence may include a poly T sequence and the 5' end may include a sequence complementary to the RNA sequence, but is not limited thereto. In the present invention, the DNA sequence may be characterized by including the same number of bases as the RNA sequence, i.e., 5 to 100 bases. Preferably, it may be characterized by including 6 to 150 nt, more preferably 20 to 100 nt, and most preferably 25 to 60 nt, including a poly T sequence, but is not limited thereto. In the present invention, the term 'RNA / DNA hybrid structure' means a structure in which an RNA sequence and a DNA sequence complementarily bind to each other to form a double strand. In one embodiment of the present invention, the DNA sequence may further comprise a poly T sequence complementary to a portion of the poly A tail at the 3' end of the mRNA structure, or may comprise the same number of nt as the additional RNA sequence, and the RNA / DNA hybrid structure may be characterized by comprising 6 to 150 bp, but is not limited thereto. In the present invention, the term 'poly A tail' is used interchangeably with 'poly (A) sequence' to mean the same thing. The length of the poly (A) sequence may vary, and may be characterized by, for example, but not limited to, a length of from about 20 adenine nucleotides to about 300 adenine nucleotides, preferably from about 40 to about 200 adenine nucleotides, more preferably from about 50 to about 100 adenine nucleotides, such as from about 60, 70, 80, 90 or 100 adenine nucleotides. As used herein, the term "nucleic acid" preferably refers to DNA or RNA. In relation to the nucleic acid, the terms "polynucleotide," "nucleotide," "nucleotide sequence," and "oligonucleotide" are used interchangeably. Polynucleotides of any length may comprise polymeric forms of nucleotides, deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure and may perform any function, known or unknown. Polynucleotides may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. Modifications to the nucleotide structure may occur before or after assembly of the polymer. Preferably, the nucleic acid is a polymer comprising or consisting of nucleotide monomers covalently linked to each other by phosphodiester bonds of a sugar / phosphate backbone. "Nucleic acid" may include modified nucleic acids, such as base-modified, sugar-modified, or backbone-modified DNA or RNA molecules. In the present invention, the mRNA may be characterized as comprising an unmodified or modified nucleic acid, and preferably may be characterized as comprising an unmodified nucleic acid. The above modified nucleic acid may be characterized by being selected from the group consisting of pseudouridine (Ψ), N1-methyl-pseudouridine (m1Ψ), 5-methyl-uridine (m5U), 2-thio-uridine (s2U), 2'-O-methyl-uridine (2'-O-methyl-U, Um), 5-methyl-cytidine (m5C), and 5-methoxy-uridine (5-methoxyuridine, 5moU), but is not limited thereto. In this specification, the term "DNA" is an abbreviation for deoxyribonucleic acid. This is a polymer made of nucleic acid molecules, i.e., nucleotides. These nucleotides are usually deoxyadenosine monophosphate, deoxythymidine monophosphate, deoxyguanosine monophosphate, and deoxycytidine monophosphate monomers, and are composed of a sugar (deoxyribose), a base, and a phosphate, and are polymerized by a unique backbone structure. The backbone structure is typically formed by the sugar moiety of the first nucleotide, i.e., deoxyribose, and the phosphate moiety of the second nucleotide, and the phosphodiester bond between adjacent monomers. The specific order of the monomers, i.e., the order of the bases linked to the sugar / phosphate backbone, is called the DNA sequence. DNA can be single-stranded or double-stranded. In double-stranded form, nucleotides of the first strand typically hybridize with nucleotides of the second strand, for example, by A / T base pairing and G / C base pairing. As used herein, the term "RNA" stands for ribonucleic acid, a nucleic acid molecule, i.e., a polymer composed of nucleotides. Examples include messenger RNA (mRNA). Nucleotides are typically adenosine monophosphate, uridine monophosphate, guanosine monophosphate, and cytidine monophosphate monomers linked together via a so-called backbone. The backbone is formed first by a sugar, such as ribose, and second by phosphodiester bonds between adjacent monomers, the phosphate moieties. The specific sequence of monomers is called an RNA sequence. Messenger RNA typically provides a nucleotide sequence that can be translated into the amino acid sequence of a specific peptide or protein. Typically, mRNA comprises a 5'-cap, a 5'UTR, an open reading frame, a 3'UTR, and a poly(A) sequence. Aside from messenger RNA, there are several noncoding forms of RNA that can be involved in the regulation of transcription and / or translation. In the present invention, the mRNA / DNA structure may be characterized by further including at least one selected from the group consisting of a 5'-untranslated region (5'-UTR) connected to both ends of the coding region; a 3'-untranslated region (3'-UTR); and a 5'-cap connected to the 5'-untranslated region; and preferably, may be characterized by having a structure represented by the following structural formula (1) or structural formula (2), but is not limited thereto. Structural formula (1): 5'-UTR - ORF - 3'-UTR - Poly (A) tail - RNA / DNA hybrid structure Structural formula (2): 5'-Cap - 5'-UTR - ORF - 3'-UTR - Poly (A) tail - RNA / DNA hybrid structure In the present invention, the term “5'-untranslated region (5'-UTR)” refers to an artificial nucleic acid molecule located 5' (i.e., "upstream") of the open reading frame and not translated into a protein. The 5'-UTR is typically understood as a specific section of an mRNA located 5' of the open reading frame of the mRNA. Typically, the 5'-UTR begins at the transcription start site and ends one nucleotide before the start codon of the open reading frame. Preferably, the 5'-UTR has a length of 20 to 200 nucleotides. The 5'-UTR may include elements for regulating gene expression, so-called regulatory elements. Such regulatory elements may be, for example, ribosome binding sites. The 5'-UTR may be post-transcriptionally modified, for example, by the addition of a 5'-Cap. The 5'-UTR of an mRNA is not translated into an amino acid sequence. The 5'-UTR sequence is typically encoded by a gene, which is transcribed into its respective mRNA during gene expression. The genomic sequence is first transcribed into a premature mRNA containing an optional intron. The premature mRNA is then further processed into a mature mRNA during a maturation process. This maturation process includes steps such as 5' capping, splicing of the premature mRNA to truncate the optional intron, modification of the 3'-end, such as polyadenylation of the 3'-end of the premature mRNA, and optional endo / exonuclease digestion. In the present invention, the 5'-UTR corresponds to the sequence of the mature mRNA located between the start codon and, for example, the 5'-Cap. Preferably, the 5'-UTR corresponds to a sequence extending from a nucleotide located 3' to the 5'-Cap, more preferably a nucleotide located immediately 3' to the 5'-Cap, to a nucleotide located 5' to the start codon of a protein coding region, preferably a nucleotide located immediately 5' to the start codon of the protein coding region. The nucleotide located immediately 3' to the 5'-Cap of mature mRNA typically corresponds to the transcription start site.The term "corresponding" means that the 5'-UTR sequence may be an RNA sequence, such as the mRNA sequence used to define the 5'-UTR sequence, or a DNA sequence corresponding to such an RNA sequence. In the present invention, the 5'-UTR may be characterized by including an IRES, but is not limited thereto. The term "IRES (Internal Ribosome Entry Site)" in the present invention is known to be an internal ribosome entry point or ribosome binding site that forms a loop structure on mRNA and induces translation initiation through a mechanism independent of the cap. By utilizing this, when an IRES is positioned between two or more genes and produced as a single vector, two genes can be simultaneously expressed on a single mRNA. Accordingly, inserting an IRES region to induce expression of a target gene is widely used in genetic recombination technology. In the present invention, the term “3'-untranslated region (3'-UTR)” refers to a portion of an artificial nucleic acid molecule located 3' (i.e., "downstream") of the open reading frame and not translated into protein. Typically, the 3'-UTR is a portion of an mRNA located between the protein coding region (ORF or CDS) and the poly(A) sequence of the mRNA. In the present invention, the term 3'-UTR may also include elements that are not encoded by the template from which the RNA is transcribed. The 3'-UTR sequence is typically encoded by a gene, which is then transcribed into mRNA during the gene expression process. The genomic sequence is first transcribed into mRNA containing optional introns. The mRNA then undergoes steps such as 5' capping, splicing, and modification of the 3'-terminus, such as polyadenylation of the 3'-terminus, and optional endo- or exonuclease digestion. In the present invention, the 3'-UTR corresponds to a sequence of a mature mRNA located between the stop codons of the protein coding region, preferably immediately 3' to the stop codon of the protein coding region, and a poly(A) sequence of the mRNA. The term "corresponding" means that the 3'-UTR sequence can be an RNA sequence, such as an mRNA sequence used to define the 3'-UTR sequence, or a DNA sequence corresponding to such an RNA sequence. Preferably, the 3'-UTR has a length of 20 to 300 nucleotides. In the present invention, the term “5’-cap” refers to an independent component that “caps” the 5’-terminus located at the 5’ start site of mRNA. Generally, the cap structure serves to initiate protein synthesis and protect mRNA from the action of nucleases, and the 5’-cap also influences translation. The 5’-cap can typically be formed by a modified nucleotide, particularly a derivative of a guanine nucleotide. Preferably, the 5’-cap is linked to the 5’-terminus via a 5’-5’-triphosphate linkage. The 5’-cap can be methylated, for example, m7GpppN, where N is the terminal 5’ nucleotide of the nucleic acid carrying the 5’-cap, typically the 5’-terminus of RNA. Additional examples of 5'-cap structures include glyceryl, inverted deoxy abasic residue (some), 4',5' methylene nucleotides, 1-(beta-D-erythrofuranosyl) nucleotides, 4'-thio nucleotides, carbocyclic nucleotides, 1,5-anhydrohexitol nucleotides, L-nucleotides, alpha-nucleotides, modified base nucleotides, threo-pentofuranosyl nucleotides, acyclic 3',4'-seconucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5 dihydroxypentyl nucleotides, some 3'-3'-inverted nucleotides, some 3'-3'-inverted abasic residues, some 3'-2'-inverted nucleotides, some 3'-2'-inverted abasic residues, 1,4-butanediol phosphate, 3'-phosphoramidate, hexyl phosphate, aminohexyl phosphate, 3'-phosphate, 3' phosphorothioate, phosphorodithioate, or a bridging or non-bridging methylphosphonate. In the present invention, the DNA vector for expressing the mRNA / DNA construct by in vitro transcription (IVT) may additionally include a promoter sequence. The promoter may be located upstream of the 5'-UTR. The promoter may include elements necessary for transcription, such as an RNA polymerase promoter. It may include a phage RNA polymerase promoter such as SP6 or T7, preferably a T7 promoter encoding an mRNA sequence. In one embodiment of the present invention, for expressing the mRNA of a target gene by the IVT method, a template DNA consisting of 5'-T7 promoter-5'UTR-target gene-3'UTR-poly(dA:dT) tail can be produced. In the present invention, “ORF” or “CDS” means a coding region encoding a target peptide or protein. The above target peptide or protein is (a) a therapeutically active protein or peptide; (b) an antigen selected from the group consisting of tumor antigens, pathogenic antigens, viral antigens, protozoal antigens, bacterial antigens, allergic antigens, and autoimmune antigens; or (c) Cas protein; Although not limited thereto, depending on the inserted gene, the mRNA / DNA construct according to the present invention can be used for gene vaccine therapy or gene therapy for autoimmune diseases, infectious diseases, cancer or tumor-related diseases, inflammatory diseases, etc. Specifically, when the mRNA / DNA construct according to the present invention is used as a vaccine for vaccine therapy, the CDS may be a region encoding all or part of a region of a viral antigen that can cause infection in humans and animals, such as influenza virus, coronavirus, varicella zoster virus, human papillomavirus, Zika virus, herpes virus, AIDS virus, SFTS virus, measles virus, Ebola virus, MERS virus, hepatitis virus, avian influenza, rabies virus, and foot-and-mouth disease virus, but is not limited thereto. In addition, when the mRNA / DNA structure of the present invention is used as a concept of gene therapy by expressing a protein or antigen, the CDS may be a region encoding all or part of the sequence of a protein drug, an antibody drug, a cancer antigen, etc., but is not limited thereto. The above disease-related antigens are 4-1BB, integrin, amyloid beta, angiopoietin (angiopoietin 1 or 2), angiopoietin-like substance 3, B-cell activating factor (BAFF), B7-H3, complement 5, CCR4, CD3, CD4, CD6, CD11a, CD19, CD20, CD22, CD30, CD33, CD38, CD52, CD62, CD79b, CD80, CGRP, Claudin-18, complement factor D, CTLA4, DLL3, EGF receptor, hemophilia factor, FGF23, folate receptor, GD2, GM-CSF, HER2, HER3, interferon receptor, interferon gamma, IgE, IGF-1 Receptor, interleukin 1, interleukin 2 receptor, interleukin 4 receptor, interleukin 5, interleukin 5 receptor, interleukin 6, interleukin 6 receptor, interleukin 7, interleukin 12 / 23, interleukin 13, interleukin 17A, interleukin 17 receptor A, interleukin 31 receptor, interleukin 36 receptor, LAG3, LFA3, NGF, PVSK9, PD-1, PD-L1, RANK-L, SLAMF7, tissue factor, TNF, VEGF and VEGF receptor, but is not limited thereto. The above antibody drug may be used without limitation if it is an antibody used for treating a disease-related condition, preferably an antibody drug for treating an antigen related to the disease, and more preferably a drug currently on the market or in the clinical trial stage, but is not limited thereto. In addition, the protein drug is a drug composed of amino acids and exhibits a disease treatment or prevention effect through the activity of the protein, and refers to a drug composed of proteins other than antibody drugs, and may be selected from the group consisting of cytokines, therapeutic enzymes, hormones, soluble receptors and fusion proteins thereof, insulin or analogues thereof, BMP (Bone Morphogenetic Protein), EPO (erythropoietin), and serum derived proteins, but is not limited thereto. As a specific example, the cytokine may be selected from the group consisting of interferon, interleukin, colony stimulating factor (CSF), tumor necrosis factor (TNF), and tissue growth factor (TGF), but is not limited thereto, and the therapeutic enzyme may be selected from the group consisting of beta-glucocerebrosidase and agalsidase beta, but is not limited thereto. In addition, the soluble receptor refers to the extracellular domain of the receptor, and its fusion protein refers to a protein in which the soluble receptor is fused with the Fc region of an antibody, etc., and includes a form in which the Fc region is fused to the TNF-α soluble receptor (e.g., a product with the generic name Etanercept), a form in which the Fc region is fused to the VEGF soluble receptor (e.g., a product with the generic name Aflibercept and similar forms), a form in which the Fc region is fused to CTLA-4 (e.g., a product with the generic name Abatacept or Belatacept and similar forms), a form in which the Fc region is fused to the interleukin-1 soluble receptor (e.g., a product with the generic name Rilonacept and similar forms), a form in which the Fc region is fused to the LFA3 soluble receptor (e.g., a product with the generic name Alefacept and similar forms), etc. Examples may include, but are not limited to: The above hormone refers to a hormone or an analogue thereof injected externally to treat or prevent diseases caused by hormone deficiency, etc., and examples thereof include, but are not limited to, human growth hormone, estrogen, and progesterone, and the above plasma-derived protein refers to a protein present in plasma, and refers to both those extracted from plasma and those produced recombinantly, and examples thereof include, but are not limited to, fibrinogen, von Willebrand Factor, albumin, thrombin, FII (Factor II), FV (Factor V), FVII (Factor VII), FVIII (Factor VIII), FIX (Factor IX), FX (Factor X), and FXI (Factor XI). The above Cas protein is for CRISPR-Cas gene editing control, and includes various Cas variants including, but not limited to, Cas9, Cas13a, Cas12a, Cas12e, Cas12f, Cas12j, Cas13, adenine base editor (ABE), and cytosine base editor (CBE). In another aspect, the present invention relates to a pharmaceutical composition for a vaccine or gene therapy comprising the mRNA / DNA structure. In another aspect, the present invention relates to a vaccine therapy or gene therapy method comprising a step of administering the mRNA / DNA construct to a subject in need of treatment or prevention. In another aspect, the present invention relates to the use of the mRNA / DNA construct for vaccine therapy and gene therapy. In another aspect, the present invention relates to the use of the mRNA / DNA construct for the manufacture of a vaccine or a gene therapy agent. The term "vaccine" in the present invention is understood to refer to a prophylactic or therapeutic substance that provides at least one antigen, preferably an immunogen. The antigen or immunogen may be derived from any material suitable for vaccination. For example, the antigen or immunogen may be derived from a pathogen, such as a bacterial or viral particle, or from a tumor or cancerous tissue. The antigen or immunogen stimulates the body's adaptive immune system, which provides an adaptive immune response. The term "prevention" in the present invention refers to any action that prevents the onset of a disease or delays its progression through the administration of the composition. Furthermore, the term "treatment" as used herein refers to any action that improves, alleviates, or completely cures the symptoms of a disease through the administration of the composition. In the present invention, the pharmaceutical composition may include a delivery means for delivering mRNA. The mRNA / DNA construct according to the present invention can be delivered via liposomes, LNPs (lipid nano-particles) or various nanoparticles. Liposomes or LNPs contain cationic lipids, non-cationic lipids, or neutral lipids, and may additionally contain other lipids such as polyethylene glycol (PEG) or cholesterol. Such mRNA delivery vehicles are specifically described in US 2018 / 0311176 A, US 2019 / 0032051 A, US 2021 / 0046192 A, WO 2018 / 081480 A, WO 2020 / 097540 A, WO 2020 / 097548 A, WO 2021 / 007278 A, etc., which are incorporated herein by reference. 상기 양이온성 지질은 US 2018 / 0311176 A, US 2019 / 0032051 A 등을 통해 구체적으로 예시되어 있으며, 예를 들어 N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) 또는 이들의 유사체, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9, 12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 1, 1′-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)didodecan-2-ol (Tech G1), 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane, β-L-arginyl-2, 3-L-diaminopropionic acid-N-palmityl-N-oleylamide trihydrochloride, N′,N′-dioctadecyl-N-4, 8-diaza-10-aminodecanoylglycine amide.
[0071] , 1,2-dilinoleyloxy-3-dimethylaminopropane, DLin-KC2-DMA, amino lipid 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA, 1), 1,2-distearloxy- / V,N-dimethylaminopropane (DSDMA), dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA), DLin-D-DMA, C12-200, 98N12-5, (20Z,23Z)-N,N-dimethylnonacosa-20,23-dien-10-amine, (17Z,20Z)-N,N-dimemylhexacosa-17,20-dien-9-amine, (1Z,19Z)-N5N-dimethylpentacosa-16,19-dien-8-amine, (13Z,16Z)-N,N-dimethyldocosa-13,16-dien-5-amine, (12Z,15Z)-N,N-dimethylhenicosa-12,15-dien-4-amine, (14Z,17Z)-N,N-dimethyltricosa-14,17-dien-6-amine, (15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-7-amine, (18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-10-amine, (15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-5-amine, (14Z,17Z)-N,N-dimethyltricosa-14,17-dien-4-amine, (19Z,22Z)-N,N-dimethyloctacosa-19,22-dien-9-amine, (18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-8-amine, (17Z,20Z)-N,N-dimethylhexacosa-17,20-dien-7-amine, (16Z,19Z)-N,N-dimethylpentacosa-16,19-dien-6-amine, (22Z,25Z)-N,N-dimethylhentriaconta-22,25-dien-10-amine, (21Z,24Z)-N,N-dimethyltriaconta-21,24-dien-9-amine, (18Z)-N,N-dimethylheptacos-18-en-10-amine, (17Z)-N,N-dimethylhexacos-17-en-9-amine, (19Z,22Z)-N,N-dimethyloctacosa-19,22-dien-7-amine, N,N-dimethylheptacosan-10-amine, (20Z,23Z)-N-ethyl-N-methylnonacosa-20,23-dien-10-amine, 1-[(11Z,14Z)-1-nonylicosa-11,14-dien-1-yl]pyrrolidine, (20Z)-N,N-dimethylheptacos-20-en-10-amine, (15Z)-N,N-dimethyleptacos-15-en-10-amine, (14Z)-N,N-dimethylnonacos-14-en-10-amine, (17Z)-N,N-dimethylnonacos-17-en-10-amine, (24Z)-N,N-dimethyltritriacont-24-en-10-amine, (20Z)-N,N-dimethylnonacos-20-en-10-amine, (22Z)-N,N-dimethylhentriacont-22-en-10-amine, (16Z)-N,N-dimethylpentacos-16-en-8-amine, (12Z,15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine, (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]eptadecan-8-amine, 1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]nonadecan-10-amine, N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine,N,N-dimeth-yl-1-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]nonadecan-10-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine, N,N-dimethyl-[(1R,2S)-2-undecylcyclopropyl]tetradecan-5-amine, N,N-dimethyl-3-{7-[(1 S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine, 1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine, 1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine, R-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propa-n-2-amine, S-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octy-loxy)propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-Roctyloxy)methyl]ethyl}pyrro-lidine, (2S)-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azet-idine, (2S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-ylo-xy]propan-2-amine, (2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]pr-opan-2-amine, N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-am-ine; (2S)-N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(o-ctyloxy)propan-2-amine, (2S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propa-n-2-amine, (2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-di-methylpropan-2-amine, 1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)pr-opan-2-amine, (2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpro-pan-2-amine, (2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amin-e,1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2R)-N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-di-en-1-yloxy]propan-2-amine, N,N-dimethyl-1-(octyloxy)-3-({8-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]-methyl}cyclopropyl]octyl}oxy)propan-2-amine, N,N-dimethyl-1-{[8-(2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-am-ine and (11E,20Z,23Z)-N,N-dimethylnonacosa-11,20,2-trien-10-amine, 5-carboxyspermylglycine dioctaoleoylamide ("DOGS"), dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide ("DPPES"), 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE), DMRIE-HP, Lipofectamine (DOSPA), 3b-(N-(N′,N′-dimethylaminoethane)-carbamoyl)cholesterol ("DC-Choi"), N-(1,2-dimyhstyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide ("DMRIE"), 1,2-Dioleoyl-3-dimethylammonium-propane ("DODAP"), DMDMA, cationic lipid-based transfection reagents TransIT-TKO, LIPOFECTIN, Lipofectamine, OLIGOFECTAMINE or DHARMAFECT, DSDMA, DODMA, DLinDMA, DLenDMA, gamma-DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DM A, DLin-K-C4-DMA, DLen-C2K-DMA, y-DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), DLin-M-C3-DMA (also known as MC3) or (DLin-MP-DMA)(also known as 1-B11), or mixtures thereof. It is not. The above non-cationic lipid is specifically exemplified by US 2018 / 0311176 A, US 2019 / 0032051 A, etc., and may be, for example, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoyl phosphatidylethanoloamine, N-succinyl phosphatidylethanolamine, N-glutaryl phosphatidylethanolamine, or lysylphosphatidylglycerol.경우에 따라서, 상기 비양이온성 지질은 예를 들어, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG)일 수 있으나, 이에 제한되는 것은 아니다. The above neutral lipids are specifically exemplified in US 2018 / 0311176 A, US 2019 / 0032051 A, etc., and may include, but are not limited to, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, dihydrosphingomyelin, cephalin, or cerebrosides. To prevent aggregation of particles generated during the above mRNA delivery, PEG fat may be included. PEG fat is specifically exemplified in US 2018 / 0311176 A, US 2019 / 0032051 A, etc., and may be, but is not limited to, PEG-diacylglycerol (DAG), PEG-dialkyloxypropyl (DAA), PEG-phospholipid, PEG-ceramide (Cer), or mixtures thereof. In another aspect, the mRNA / DNA construct according to the present invention can be delivered via nanoparticles, for example, gold nanoparticles. The gold nanoparticles may have a modified surface. Specific examples of modifications are described in Acc Chem Res. 2019 June 18; 52(6): 1496-1506 and Pharmaceutics 2021, 13, 900, which are incorporated herein by reference. The mRNA / DNA structure can be delivered to cells by linking gold nanoparticles and forming a complex with a cationic endosomal disruptive polymer (Nature Biomedical Engineering volume 1, pages 889-901 (2017)). The cationic endosomal disruptive polymer can be, for example, a block copolymer of polyethylene imine, poly(arginine), poly(lysine), poly(histidine), poly-[2-{(2-aminoethyl)amino}-ethyl-aspartamide] (pAsp(DET)), poly(ethylene glycol) (PEG) and poly(arginine), a block copolymer of PEG and poly(lysine), or a block copolymer of PEG and poly{N-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} (PEG-pAsp(DET)). In some cases, gold particles with arginine-modified surfaces can be used. The arginine-modified gold particles can be assembled with a nuclease or a polynucleotide encoding it and / or a cleavage factor or a polynucleotide encoding it. This allows them to fuse with the membrane of the target cell and translocate into the cytoplasm (ACS Nano. 2017, 11:2452-2458). In another aspect, peptides may be used to deliver mRNA / DNA constructs according to the present invention. The peptide must have a cationic charge to electrostatically interact with the anionic phosphate group of the nucleic acid, and may include positively charged amino acids to electrostatically interact with the phosphate group. Specific details of peptides usable for mRNA delivery are described in AIMS Biophysics, 7(4): 323-338, which is incorporated herein by reference. The peptide that can be used for delivery of the mRNA / DNA construct may include protamine. Protamine is a small, cationic, arginine-rich nuclear protein that contributes to the stability of DNA during spermatogenesis in the testis. Protamine stabilizes mRNA molecules, enabling efficient delivery. A protamine-mRNA complex is specifically described in US 9352028 B, which is incorporated herein by reference. Cell-penetrating peptides (CPPs) may also be promising cationic molecules for delivery of mRNA / DNA constructs. Non-limiting examples of such cationic molecules include, but are not limited to, amphipathic CPPs such as the arginine-rich RALA peptide (WEARLARALARALARHLARALARALRACEA), RALA, LAH4 (KKALLALALHHLAHLALHLALALKKA), and LAH4-L1 (KKALLAHALHLLALLALHLAHALKKA). In addition to the liposomes or LNPs described above, peptides may be additionally included for mRNA delivery, if desired. These peptides can provide nucleic acid packaging and protect DNA or RNA from degradation either intracellularly or extracellularly. Examples of such peptides are specifically described in US 2021 / 0170046 A, which is incorporated herein by reference, but is not limited thereto. The pharmaceutical composition according to the present invention may contain a pharmaceutically effective amount of the mRNA / DNA construct alone, or may contain one or more pharmaceutically acceptable carriers, excipients, or diluents. The pharmaceutically effective amount herein refers to an amount sufficient to prevent, improve, or treat the target disease. The above “pharmaceutically acceptable” means physiologically acceptable and does not typically cause allergic reactions such as gastrointestinal upset or dizziness or similar reactions when administered to humans. Examples of the carrier, excipient, and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, the pharmaceutical composition may further include fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, and preservatives. The term "carrier" is defined as a compound that facilitates the introduction of mRNA / DNA constructs into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into the cells or tissues of living organisms. The term "diluent" is defined as a compound that stabilizes the biologically active form of the target compound and is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the field. A commonly used buffer solution is phosphate-buffered saline, as it mimics the salt content of human body fluids. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely alter the biological activity of a compound. A pharmaceutical composition containing the mRNA / DNA construct according to the present invention may be administered to a patient as such or as a pharmaceutical composition mixed with other active ingredients or with suitable carriers or excipients, such as in combination therapy. The pharmaceutical composition of the present invention can be administered through various routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and the dosage of the active ingredient can be appropriately selected depending on various factors such as the route of administration, the patient's age, sex, weight and the patient's severity. Pharmaceutical compositions suitable for use in the present invention include compositions containing an mRNA / DNA construct encoding an active ingredient in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount refers to an amount of a compound effective to prolong the survival of a subject being treated, or to prevent, alleviate, or relieve symptoms of a disease. Determination of a therapeutically effective amount is within the capabilities of those skilled in the art, particularly in light of the detailed disclosure provided herein. In the present invention, “subject” means a mammal suffering from or at risk of a condition or disease that can be alleviated, suppressed or treated by administering an mRNA / DNA construct according to the present invention, and preferably means a human. The dosage of the mRNA / DNA construct of the present invention to the human body may vary depending on the patient's age, body weight, sex, dosage form, health condition, and degree of disease. The toxicity and therapeutic efficacy of compositions comprising the mRNA / DNA constructs described herein can be estimated by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the lethal dose to 50% of a population), the ED50 (the dose that has a therapeutic effect on 50% of a population), and the IC50 (the dose that has a therapeutic inhibitory effect on 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio of the LD50 to the ED50 (or IC50). Compounds that exhibit a high therapeutic index are preferred. Data obtained from these cell culture assays can be used to estimate a range of doses for use in humans. The dosage or application amount of such compounds is preferably within a range of circulating concentrations that include the ED50 (or IC50) with little or no toxicity. The term “administration” of the present invention means an act of introducing the pharmaceutical composition of the present invention into a subject by any appropriate method, and the route of administration may be various routes, such as oral or parenteral, as long as it can reach the target tissue. The pharmaceutical composition of the present invention may be administered via any conventional route as long as it can reach the target tissue. The pharmaceutical composition of the present invention is not particularly limited thereto, but may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, intranasally, intrapulmonary, or rectally, depending on the intended use. Furthermore, the composition may be administered via any device capable of transporting the active ingredient to target cells. The pharmaceutical composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. It can also be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer the amount that achieves maximum efficacy with the minimum amount possible without causing side effects. The pharmaceutical composition according to the present invention may be formulated as an injectable formulation such as an aqueous solution, suspension, emulsion, etc., but is not limited thereto, and is preferably provided in a lyophilized form. For the preparation of a lyophilized formulation, a method commonly known in the art to which the present invention pertains may be used, and a stabilizer for lyophilization may be added. Furthermore, the composition may be preferably formulated according to each disease or ingredient using an appropriate method in the art or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA). Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples. Example 1: Preparation of a novel mRNA / DNA hybrid nucleic acid structure according to the present invention. Example 1-1: Preparation of pDNA template for IVT mRNA synthesis PCR was performed using DNA vectors (pUCIDT-AMP-DsRed Express2, Luciferase-pCDNA3, pUC-pc-EPO) containing the T7 promoter, 5'UTR, open reading frame, and 3'UTR as a transcription template for IVT mRNA synthesis. PCR was performed using TOPsimple™ PCR DryMIX-Forte (Enzynomics, Korea), and the specific PCR conditions are shown in Table 1 below. The amplified PCR reaction products were purified using AccuPrep® PCR Purification Kit (Bioneer, Korea). After each of the above reactions was completed, the reaction products were electrophoresed on a 1% agarose gel at 100 V for 30 minutes to confirm the PCR reaction products, and the results are shown in Figures 2a to 2c. First, in order to perform PCR using a DNA vector (pUCIDT-AMP-DsRed Express2) containing an open reading frame and 3'UTR encoding the model protein Red Fluorescence Protein (RFP) as a template, a forward primer (FP) containing the same base sequence of 27 nt at the end of the vector DNA was used, and in order to insert a poly(dA:dT) sequence into the DNA template for IVT mRNA synthesis, a reverse primer (RP) containing the same base sequence of 29 nt binding to the end of the 3'UTR of the template followed by a 120 nt poly(T) tail was used. Using the above forward and reverse primers, PCR was performed using the DNA vector (pUCIDT-AMP-DsRed Express2) as a template, and as a result, a DNA template containing a T7 promoter, 5'UTR, open reading frame (ORF), 3'UTR, and a 120 bp poly(dA:dT) tail was created, which was named pRFP. In addition, in order to introduce the hybrid structure, the forward primer (FP) containing the 27 nt identical base sequence present at the end of the vector DNA was used, and PCR was performed using two additional sequences of 21 nt for introducing the hybrid structure and a reverse primer (RP) containing the same base sequence of 29 nt followed by 51 nt and the poly(T) sequence for inserting the primer into the vector. As a result, DNA templates were produced in which a 120 bp poly(dA:dT) tail and three additional sequences were introduced following the 3' end of the 3'UTR of the DNA template. Among these, two DNA templates having different sequences with an additional introduced sequence length of 21 bp were named pRFP21A and pRFP21B, and the DNA template with an additional sequence length of 51 bp was named pRFP51C. Next, in order to perform PCR using a DNA vector (Luciferase-pCDNA3) containing an open reading frame and 3'UTR encoding a model protein, luciferase (Firefly Luc), as a template, a forward primer (FP) containing 18 nt of the same base sequence present at the end of the vector DNA was used, and in order to insert a poly(dA:dT) sequence into the DNA template for IVT mRNA synthesis, a reverse primer (RP) containing 18 nt of the same base sequence binding to the end of the 3'UTR of the template followed by a 120 nt poly(T) tail was used. Using the above forward primer and reverse primer, PCR was performed using the DNA vector (Luciferase-pCDNA3) as a template, and as a result, a DNA template containing a T7 promoter, 5'UTR, open reading frame (ORF), 3'UTR, and a 120 bp poly(dA:dT) tail was created, which was named pLuc. In addition, in order to introduce the hybrid structure, the forward primer (FP) containing the 18 nt identical base sequence existing at the end of the vector DNA was used, and PCR was performed using two additional sequences of 21 nt for introducing the hybrid structure and a reverse primer (RP) containing 62 nt followed by a poly(T) sequence and 18 nt identical base sequence for inserting the primer into the vector. As a result, DNA templates in which a 120 bp poly(dA:dT) tail and three additional sequences were introduced at the 3' end of the 3'UTR of the DNA template were manufactured. Among these, two DNA templates having different sequences with an additional introduced sequence length of 21 bp were named pLuc21A and pLuc21B, and the DNA template with an additional sequence length of 62 bp was named pLuc62C. Next, in order to perform PCR using a DNA vector (pUC-pC EPO) containing an open reading frame and 3'UTR encoding erythropoietin (EPO), a therapeutic protein, as a template, a forward primer (FP) containing 27 nt of the same base sequence present at the end of the vector DNA was used, and in order to insert a poly(dA:dT) sequence into the DNA template for IVT mRNA synthesis, a reverse primer (RP) containing 18 nt of the same base sequence binding to the end of the 3'UTR of the template followed by a 120 nt poly(T) tail was used. Using the above forward and reverse primers, PCR was performed using the DNA vector (pUC-pC EPO) as a template, and as a result, a DNA template containing a T7 promoter, 5'UTR, open reading frame (ORF), 3'UTR, and a 120 bp poly(dA:dT) tail was created, which was named pEPO. In addition, in order to introduce the hybrid structure, the forward primer (FP) containing the 27 nt identical base sequence existing at the end of the vector DNA was used, and PCR was performed using two additional sequences of 21 nt for introducing the hybrid structure and a reverse primer (RP) containing the same base sequence of 62 nt followed by a poly(T) sequence and 18 nt for inserting the primer into the vector. As a result, DNA templates in which a 120 bp poly(dA:dT) tail and three additional sequences were introduced at the 3' end of the 3'UTR of the DNA template were manufactured. Among these, two DNA templates having different sequences with an additional introduced sequence length of 21 bp were named pEPO21A and pEPO21B, and the DNA template with an additional sequence length of 62 bp was named pEPO62C. DNA templates with 120 nt of poly(T) tail and additional sequences introduced at 3' right next to the 3'UTR were prepared using reverse primers (RP) containing two additional sequences of 21 nt each and a poly(T) sequence of 62 nt for introducing a hybrid structure and 18 nt of the same sequence for future insertion into a vector. The two templates with the additional sequence of 21 nt in length were named pEPO21A and pEPO21B, and the DNA template with the additional sequence of 62 nt in length was named pEPO62C. That is, the forward / reverse primers used were based on the following configuration. Forward primer 1: 5'-homologous DNA sequence that specifically binds to the DNA vector Primer sequence-3' Reverse primer 1: 5'-additional sequence (21A or 21B or 62 nt)-poly(T)-DNA vector-homologous DNA sequence that specifically binds to the primer sequence-3' The DNA vectors, all primer sequences, and annealing sequences used in the present examples and experimental examples are shown in Table 2 below. All sequences were provided by IDT and Bioneer (gene synthesis service). Example 1-2: Production of IVT mRNA using each pDNA as a template In vitro transcription (IVT) was performed using the pDNA prepared in Example 1-1 to synthesize IVT mRNA. In vitro transcription was performed using linearized template DNA generated through PCR using a reaction solution (EZ™ MEGA T7 Transcription Kit, enzynomics, Korea) containing T7 RNA polymerase and rATP, rUTP, rCTP, rGTP, and a Cap analogue. The template DNA was removed by treatment with DNase I, and only mRNA was recovered. As a comparative example, in vitro transcription was performed using a reaction solution (EZ™ MEGA T7 Transcription Kit, enzynomics, Korea) containing T7 RNA polymerase and rATP, pUTP (pseudouridine-5'-Triphosphate, Trilink, USA), rCTP, rGTP, and a Cap analogue to synthesize mRNA in which the uridine base was modified to pseudouridine, and DNase I was treated to remove template DNA and recover only mRNA. The reaction solutions of the IVT mRNA experimental examples and comparative examples were each placed in a PCR tube and incubated at 37°C for 2 hours. Then, 2 μl of DNase I (enzynomics, Korea) was added and the reaction was performed at 37°C for 15 minutes. The reaction products were purified using the RNeasy Mini Kit (Qiagen, USA). All components constituting the reaction solution and their volumes and concentrations are shown in Table 3 below. The mRNA synthesized through this included a 5'-cap produced by adding a cap analog to the transcription reaction at the 5' end. Example 1-3: Preparation of a novel mRNA / DNA hybrid nucleic acid structure In Example 1-2, IVT mRNA was prepared by annealing a DNA oligo having a sequence complementary to the additional sequence introduced into the 3' end of the poly (A) tail of the mRNA, thereby preparing an mRNA / DNA novel nucleic acid structure in which an RNA / DNA hybrid structure was introduced into the 3' end of the mRNA. The conditions for annealing are sequence-dependent and may vary depending on environmental variables, but in this example, the conditions for annealing a 25nt DNA oligo to the 3' end of the mRNA were as follows: after releasing the secondary structure at 65°C, the temperature was slowly lowered to 30°C, and fast cooling (quenching) was performed at 4°C. The conditions for annealing the 60nt and 65nt DNA oligos to the 3' end of the mRNA were as follows: after releasing the secondary structure at 75°C, the temperature was slowly lowered to 30°C, and fast cooling (quenching) was performed at 4°C. The manufactured mRNA / DNA novel nucleic acid structure is schematically illustrated in Figure 1. Example 1-4: Purification and identification of IVT mRNA To remove dsRNA (double-stranded RNA), an impurity generated during IVT mRNA synthesis, cellulose purification (Cel-p) was performed and the following paper was referenced (Mol Ther Nucleic Acids. 2019 Apr 15; 15:26-35). Specifically, chromatography buffer (10 mM HEPES (pH 7.2), 0.1 mM EDTA, 125 mM NaCl, 16% ethanol) was prepared, 0.2 g of cellulose powder (Cellulose, sigma-Aldrich, USA) was added per 1 ml of buffer, and mixed well at room temperature for 10 minutes to form a slurry. 700 μl of this slurry was transferred to a spin column (Nucleo-spin, Merck, Germany) and centrifuged at 14,000 g for 1 min. Create two columns per sample. Discard the solution that has flowed down the column, add 500 μl of new chromatography buffer to the column, mix the cellulose powder well for 5 minutes, centrifuge at 14,000 g for 1 minute, and discard the solution that has flowed down the column. This completes the pre-washed cellulose column. Add 100-500 μg of IVT mRNA to 500 μl of new chromatography buffer, add it to the pre-washed cellulose column, mix well for 30 minutes, and centrifuge at 14,000 g for 1 minute. During this process, dsRNA is separated by associating with cellulose, and only ssRNA (single-stranded RNA) flows down the column. The solution that has flowed down is added to the new pre-washed column, mixed well for 30 minutes, and centrifuged at 14,000 g for 1 minute. The solution ssRNA was transferred to Amicon Ultra-0.Transfer to a 5 centrifugal filter (Merck, USA) and centrifuge at 14,000 g for 3 minutes to remove the buffer, then fill an Amicon Ultra-0.5 filter with DEPC water (Enzynomics, Korea) and centrifuge again at 14,000 g for 3 minutes to replace the chromatography buffer with DEPC water. To confirm whether dsRNA was properly removed by the cellulose purification method (Cel-p), Dot-blot was performed using J2 antibody (J2 Anti-body, Scicons, Hungary) that specifically binds to dsRNA of 40 bp or more. After reacting 250 ng of IVT mRNA with J2 antibody diluted 1:5,000, the binding of dsRNA was confirmed using Chemi-Doc imaging equipment (Bio-Rad, USA). The results are shown in Figure 3. In IVT mRNA (Cel-p(-)) that was not purified from cellulose, the reaction of J2 antibody binding to dsRNA was confirmed, but in IVT mRNA (Cel-p(+)) that was purified from cellulose, dsRNA was well removed, so no J2 antibody reaction was observed. Example 1-5: Confirmation of RNA / DNA Hybrid Structure of Novel mRNA / DNA Nucleic Acid Structure To confirm whether a novel mRNA / DNA nucleic acid structure was successfully created by introducing a DNA oligo into the additional sequence at the 3' end of the IVT mRNA and introducing an RNA / DNA hybrid structure at the 3' end of the mRNA, the material before and after annealing of the DNA oligo was electrophoresed on a 15% PAGE gel to confirm the results. Specifically, mRNA / DNA25A and mRNA / DNA25B, which are nucleic acid structures in which a 25-bp RNA / DNA hybrid duplex was introduced to the 3' end of mRNA, were prepared by annealing 25 nt of DNA Oligo (19 nt of additional sequence - 6 dTs = 25 nt DNA oligo) that complementarily binds to the 6 poly (A) tails at the 3' end, which are part of the poly (A) tail consisting of 120 nt, following the 19 nt of sequence added to the poly (A) tail end of mRNA, and mRNA / DNA60C was prepared by annealing 60 nt of DNA oligo (49 nt of additional sequence - 11 dTs = 60 nt DNA oligo) that complementarily binds to the 11 nt poly (A) tail, which is part of the poly (A) tail of mRNA, and the 49 nt of sequence added to the 3' end thereof. To confirm whether the DNA oligos were properly introduced into the 3' end of the mRNA, a 15% PAGE gel was used to compare the bands of the DNA oligos (25-mer, 60-mer) before and after annealing. As a result, it was confirmed that the DNA oligos were properly introduced into the mRNA structure after annealing, and all DNA oligo bands disappeared. Through these results, it was confirmed that all DNA oligos were stably bound to the additional sequence at the 3' poly (A) tail end of the mRNA, and an mRNA / DNA novel nucleic acid structure in which an RNA / DNA hybrid structure was successfully introduced into the 3' end of the mRNA was stably formed regardless of the sequence or length of the DNA oligo. This result is shown in Fig. 4a. In addition, to further confirm whether the novel mRNA / DNA nucleic acid structure in which the RNA / DNA hybrid structure was introduced into the 3' end of the mRNA by introducing a DNA oligo into the additional sequence of the poly (A) tail end of the IVT mRNA was well formed, Dot-blot was performed using the S9.6 antibody (Kerafast, USA) that specifically binds to RNA / DNA hybrid. After reacting 1 μg of IVT mRNA with the S9.6 antibody diluted 1:20,000, the binding of RNA / DNA was confirmed using Chemi-Doc imaging equipment (Bio-Rad, USA), and the result is shown in Fig. 4b. No reaction by the S9.6 antibody was observed in the ssRNA (single-stranded RNA) mRNA, but it was confirmed that the S9.6 antibody reaction was observed in the mRNA / DNA25B and mRNA / DNA60C structures in which the RNA / DNA hybrid structure was introduced into the 3' end of the mRNA. Through the above results, it was confirmed that an RNA / DNA hybrid structure was stably formed at the 3' end of mRNA, regardless of the length of the RNA / DNA sequence, thereby forming a novel mRNA / DNA nucleic acid structure. The sequence of the manufactured novel nucleic acid structure is described in Table 4 below. Example 2: Evaluation of the Firefly Luciferase Protein Expression Ability of IVT mRNA and mRNA / DNA Hybrid Novel Nucleic Acid Constructs The ability of mRNA encoding luciferase protein and novel nucleic acid constructs, mRNA / DNA25A, mRNA / DNA25B, and mRNA / DNA65C, which are mRNA / DNA25A, mRNA / DNA25B, and mRNA / DNA65C constructs, to express Firefly luciferase protein was confirmed. Specifically, 293T cells (Human Embryonic Kidney-293T, ATCC, USA) were seeded in a 96-well plate at a density of 2 x 10 per well. 4 After seeding and culturing in a CO2 incubator for more than 18 hours, each nucleic acid construct was transfected into the cells at a dose of 70 ng / well using a transfection reagent (Lipofectamine™ 2000, Invitrogen, USA). 18 hours after transfection, luminescence was measured using a Luciferase assay system (Bright-Glo™ Luciferase Assay System, Promega, USA) reagent to confirm the ability of the cells to express firefly luciferase protein, and the result was expressed as RLU (Relative Light Unit, Luciferase activity) value, and the result is shown in Fig. 5. The RLU value increased as the protein expression efficiency increased, and it was confirmed that the novel mRNA / DNA nucleic acid construct in which the RNA / DNA hybrid structure was introduced at the 3' end of the mRNA showed higher protein expression than the single-stranded mRNA regardless of the sequence and length of the RNA / DNA hybrid structure part, and this result was confirmed to be statistically significant. Statistical analysis was performed using Graphpad Prism 6 (t-test) software. Example 3: Preparation and Evaluation of Lipid Nanoparticles Encapsulating IVT mRNA and mRNA / DNA Hybrid Novel Nucleic Acid Structures To prepare lipid nanoparticles (LNPs) containing mRNA encoding RFP and novel nucleic acid structures mRNA / DNA25A, mRNA / DNA25B, mRNA / DNA60C encoding EPO, and novel nucleic acid structures mRNA / DNA25A, mRNA / DNA25B, mRNA / DNA65C encoding EPO, the following paper was referenced (Molecular Therapy: Nucleic Acids Vol. 15 April 2019). Specifically, ionizable lipid SM-102 (MCE, USA), cholesterol (Cholesterol powder, Avanti, USA), phospholipid (DSPC, 18:0 PC, Avanti, USA), and DMG-PEG 2000 (Avanti, USA) were dissolved in ethanol at a molar ratio of 50:38.5:10:1.5, respectively, and 20 μg of each nucleic acid construct was diluted in a 25 mM sodium acetate solution with a pH of 5. The nucleic acid constructs diluted in ethanol and sodium acetate aqueous solutions containing ionizable lipids, cholesterol, phospholipids, and DMG-PEG 2000 were used in a volume ratio of 1:3 to prepare lipid nanoparticles encapsulating nucleic acid constructs using a microfluidic cartridge (Ignite NxGen Cartridge, PNI) and equipment (NanoAssemblr® Ignite™, PNI, Canada) at a flow rate of 12 ml / min. Specifically, the weight ratio of ionizable lipid SM-102 and each nucleic acid structure was 1:13. To remove ethanol from the lipid nanoparticles encapsulating the nucleic acid structure and to adjust the pH of the lipid nanoparticles to neutral, the lipid nanoparticles encapsulating the nucleic acid structure were placed in a 3,500 MWCO dialysis cassette (Slide-A-Lyzer™ Dialysis Cassettes, Thermo fisher, USA) and dialyzed for more than 18 hours using 8% Tris-sucrose buffer adjusted to pH 7.4-7.5. The size and polydispersity index (PDI) of the lipid nanoparticles encapsulating the nucleic acid structure were measured using dynamic light scattering (DLS) with a Zetasizer (Malvern Instrument, UK). To measure the encapsulation efficiency (%) of lipid nanoparticles encapsulating mRNA and mRNA / DNA hybrid novel nucleic acid structures, respectively, a Ribogreen assay (Quant-iT™ RiboGreen® RNA, Invitrogen, USA) was performed. Specifically, the nucleic acid structures encapsulated in lipid nanoparticles were diluted to a concentration of 5 μg / ml using 1X TE buffer and then loaded 50 μl each into a black 96-well plate. After loading 4 wells per lipid nanoparticle, 50 μl of 1x TE buffer was added to 2 wells and 50 μl of 2% Triton-X buffer was added to 2 wells, followed by incubation at 37°C for 10-15 minutes to disaggregate the lipid nanoparticles with the 2% Triton-X buffer. 100 μl of Ribogreen reagent was treated per well, and the fluorescence value (Excitation 485 nm, Emission 528 nm) of the released nucleic acid before and after lipid nanoparticle degradation was measured using a microreader (VICTOR NIVO™, Perkin Elmer, USA). Encapsulation efficiency (%) was calculated by subtracting the fluorescence value of the well treated with only 1X TE buffer from the fluorescence value of the well treated with 2% Triton-X buffer, dividing the result by the fluorescence value of the well treated with 2% Triton-X buffer, and multiplying the result by 100. The results are shown in Figs. 6a and 6b, and it was confirmed that all nucleic acid structures were well encapsulated in lipid nanoparticles by more than 90%, and homogeneous lipid nanoparticles with a diameter of 90 to 110 nm were produced. Example 4: Evaluation of RFP expression ability of lipid nanoparticles encapsulating novel nucleic acid structures with IVT mRNA and mRNA / DNA hybrids I To evaluate the protein expression ability of mRNA LNPs, mRNA / DNA25A LNPs, mRNA / DNA25B LNPs, and mRNA / DNA60C LNPs, which are novel nucleic acid structures encapsulating mRNA and mRNA / DNA hybrids encoding RFP, in lipid nanoparticles, expression of RFP red fluorescent protein was confirmed using 293T cells. Specifically, 293T cells were seeded at 2x10 per well in a 96-well plate. 4 After seeding and culturing in a CO2 incubator for more than 18 hours, the lipid nanoparticles encapsulating each nucleic acid structure were transfected into the cells at a dose of 70 ng mRNA / well. After 3, 6, 18, 24, and 48 hours of transfection, the medium was removed, and 100 μl of cell lysis buffer (CelLytic™ M, Sigma-aldrich, USA) was added to lyse the cells and elute the intracellular RFP red fluorescent protein. The fluorescence value of the RFP red fluorescent protein was measured using a microreader (Excitation 530 nm, Emission 580 nm). The fluorescence values of mRNA LNP, mRNA / DNA25A LNP, mRNA / DNA25B LNP, and mRNA / DNA60C LNP were quantified compared to the fluorescence value of BLK without any treatment, and are shown in Fig. 7a and Fig. 7b along with the AUC graph. As the protein expression efficiency increased, the RFP expression value and AUC value increased, and it was confirmed that the novel mRNA / DNA nucleic acid structure in which the RNA / DNA hybrid structure was introduced at the 3' end of the mRNA showed higher protein expression than the single-stranded mRNA regardless of the sequence and length of the RNA / DNA hybrid part, and this result was confirmed to be statistically significant. Statistical analysis was performed using Graphpad Prism 6 (t-test) software. Example 5: Evaluation of RFP expression ability of lipid nanoparticles encapsulating novel nucleic acid structures with IVT mRNA and mRNA / DNA hybrids II To evaluate the protein expression ability of mRNA LNP, mRNA / DNA25A LNP, mRNA / DNA25B LNP, and mRNA / DNA60C LNP, which encapsulate mRNA encoding RFP and mRNA / DNA hybrid novel nucleic acid structures into lipid nanoparticles, expression of RFP red fluorescent protein was confirmed using THP-1 human monocyte cells (ATCC, USA). Specifically, THP-1 human monocyte cells were seeded at 3x10 per well in a 96-well plate. 5Cells were seeded with a 5-well plate and treated with 5 ng of PMA (phorbol-12-myristate-13-acetate) for 3 hours to induce differentiation into macrophages. After culturing for more than 72 hours, the nucleic acid structures encapsulated in lipid nanoparticles were transfected into the cells at a dose of 100 ng mRNA / well, respectively. 18 hours after transfection, the medium was removed, and 100 μl of cell lysis buffer (CelLytic™ M, Sigma-aldrich, USA) was added to lyse the cells and elute the intracellular RFP red fluorescent protein. The fluorescence value of the RFP red fluorescent protein was measured using a microreader (Excitation 530 nm, Emission 580 nm). The fluorescence values of mRNA LNP, mRNA / DNA25A LNP, mRNA / DNA25B LNP, and mRNA / DNA60C LNP are numerically compared to the fluorescence value of BLK without any treatment, and the results are shown in Fig. 8. As the protein expression efficiency increases, the RFP expression value increases, and it was confirmed that the novel mRNA / DNA nucleic acid structure in which the RNA / DNA hybrid structure was introduced at the 3' end of the mRNA showed higher protein expression than the single-stranded mRNA regardless of the sequence and length of the RNA / DNA hybrid part, and this result was confirmed to be statistically significant. Statistical analysis was performed using Graphpad Prism 6 (t-test) software. Example 6: Evaluation of the in vivo expression ability of lipid nanoparticles encapsulating novel nucleic acid structures of IVT mRNA and mRNA / DNA hybrids. To evaluate the in vivo protein expression ability of mRNA LNP, mRNA / DNA25A LNP, mRNA / DNA25B LNP, mRNA / DNA65C LNP, and Modified mRNA LNP, which encapsulate novel nucleic acid constructs encoding EPO (erythropoietin) protein into lipid nanoparticles, BALB / c male mice (7 weeks old, Orient Bio) were used. Each nucleic acid construct encapsulated in lipid nanoparticles was injected into mice by retro-orbital injection at a dose of 2 μg mRNA. In this example, to directly compare the protein expression ability of the mRNA / DNA novel nucleic acid construct with that of the modified mRNA, mRNA in which the uridine base of the mRNA was modified to pseudouridine was encapsulated into lipid nanoparticles and then injected into mice at the same dose as the novel nucleic acid construct. Blood samples were collected 3 and 6 hours after injection, and plasma was separated by centrifugation. EPO expression ability was evaluated using an EPO sandwich enzyme-linked immunosorbent assay (ELISA). Specifically, Capture EPO antibody (Human Erythropoietin Antibody pair, Abcam, UK) was diluted 1:1,000 in 1X ELISA Carbonate coating buffer, added 100 μl per well to an immuno-96-well plate, incubated overnight at 4°C, and washed with 0.05% PBST to ensure good antibody coating. After blocking with 5% bovine serum albumin (BSA) for 2 hours, 100 μl of diluted serum was added to each well, incubated at 37°C for 2 hours, the serum was removed, washed twice with 0.05% PBST, and the antibody was biotinylated (Biotin Conjugation Kit, Abcam, UK). After diluting biotinylated detector antibody 1:1,000 in 5% bovine serum albumin (BSA) buffer, add 100 μl per well, incubate for 2 hours at room temperature, and wash four times with 0.05% PBST. After diluting streptavidin-HRP (Abcam, UK), which binds strongly to biotin, 1:10,000 in 5% bovine serum albumin (BSA) buffer, add 100 μl per well, incubate for 30 minutes at room temperature in a light-shielded state, remove streptavidin-HRP, and wash four times with 0.05% PBST. 100 μl of TMB solution (TMB Substrate Solution, Thermo fisher, USA) was added per well and incubated at room temperature for 15-30 minutes. When a color change was observed, 100 μl of Stop Solution (Stop Solution for TMB Substrates, Thermo fisher, USA) was added to stop the reaction, and the absorbance was measured at a wavelength of 450 nm using a microreader. The results are shown in Figs. 9a and 9b. When EPO expression was confirmed using the EPO sandwich ELISA test, the EPO expression ability of the novel mRNA / DNA nucleic acid construct in which the RNA / DNA hybrid structure was introduced at the 3' end of the mRNA was confirmed to be superior to that of single-stranded mRNA. The improved EPO expression ability of the novel mRNA / DNA nucleic acid construct was confirmed to be similar to that of the modified mRNA, and these results imply that the introduction of the RNA / DNA hybrid structure at the 3' end of the mRNA can increase the expression of the therapeutic protein (EPO) without chemical base modification of the mRNA. Example 7: Confirmation of the interferon (IFN) modulating effect of novel nucleic acid constructs containing IVT mRNA and mRNA / DNA hybrids. The production or secretion of interferons (IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω) was confirmed using human monocytic cells, THP-1 Dual™ cells (Invivogen, Hong Kong), using mRNA encoding RFP and novel mRNA / DNA hybrid nucleic acid constructs, mRNA, mRNA / DNA25A, mRNA / DNA25B, mRNA / DNA60C, and Modified mRNA. THP1-Dual™ cells are characterized by the secreted luciferase gene under the control of the ISG54 (IFN-stimulated gene) promoter, an interferon-stimulated gene, along with five interferon (IFN)-stimulated response elements, and the interferon-inducing ability can be confirmed by assessing luciferase activity. Specifically, THP-1 Dual™ cells were seeded at 3x10 per well in a 96-well plate. 5After seeding, differentiation into macrophages was induced by treating with 5 ng of PMA (phorbol-12-myristate-13-acetate) for 3 hours. After culturing the cells for more than 72 hours, 200 ng each of mRNA, mRNA / DNA25A, mRNA / DNA25B, mRNA / DNA60C, and modified mRNA were transfected. 18-24 hours after transfection, 25 μl of the cell supernatant was reacted with 75 μl of Quanti-Luc (Invivogen, Hong Kong) reagent, and luciferase activity was measured using a luminometer. The Lucia luciferase activity level was confirmed, and the results were expressed as ISG54 activity (activity value) and are shown in Fig. 10. A lower ISG54 activity value was measured in the mRNA / DNA novel nucleic acid structure in which an RNA / DNA hybrid structure was introduced at the 3' end of the mRNA than in the single-stranded mRNA structure. In addition, the interferon-inducing ability of the mRNA / DNA novel nucleic acid structure was confirmed to have an equivalent level of induction ability, although statistically insignificant, compared to the modified mRNA, which is well known to show low interferon-inducing ability. These results show that the mRNA / DNA novel nucleic acid structure having an RNA / DNA hybrid structure at the 3' end of the mRNA has the effect of reducing the interferon-inducing ability to a level similar to that of the modified mRNA without modifying the mRNA base. These results suggest that the mRNA / DNA novel nucleic acid structure having an RNA / DNA hybrid structure at the 3' end of the mRNA can reduce the immune-inducing ability of unmodified IVT mRNA to a level similar to that of the modified mRNA. While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. An mRNA / DNA structure comprising a coding region (ORF) encoding a target peptide or protein; and an RNA / DNA hybrid structure linked to the 3' end of a poly A tail; The above RNA / DNA hybrid structure is an mRNA / DNA structure characterized in that an additional RNA sequence and a DNA sequence complementary to the additional RNA sequence are complementarily bound to form a double strand.
2. An mRNA / DNA structure according to claim 1, wherein the additional RNA sequence comprises 5 to 100 nucleotides.
3. An mRNA / DNA structure according to claim 1, wherein the DNA sequence further comprises a poly T sequence complementary to a portion of the poly A sequence at the 3' end of the poly A tail.
4. An mRNA / DNA structure according to claim 3, characterized in that the DNA sequence comprises 6 to 150 nucleotides.
5. An mRNA / DNA structure characterized in that it further comprises at least one selected from the group consisting of a 5'-untranslated region (5'-UTR) connected to both ends of the coding region; a 3'-untranslated region (3'-UTR); and a 5'-cap connected to the 5'-untranslated region in the first paragraph.
6. In paragraph 1, the target peptide or protein is (a) a therapeutically active protein or peptide; (b) an antigen selected from the group consisting of tumor antigens, pathogenic antigens, viral antigens, protozoal antigens, bacterial antigens, allergic antigens, and autoimmune antigens; or (c) Cas protein; An mRNA / DNA structure characterized by:
7. A pharmaceutical composition for a vaccine or gene therapy comprising an mRNA / DNA structure according to any one of claims 1 to 6.
8. A vaccination or gene therapy method comprising a step of administering an mRNA / DNA construct according to any one of claims 1 to 6.
9. Use of an mRNA / DNA construct according to any one of claims 1 to 6 for the manufacture of a vaccine or gene therapy product.
Citation Information
Patent Citations
Nucleic acid construct for simultaneous gene expression and suppression
KR102224580B1
Electro-mechanical brake and vehicle having the same
KR102401768B1
Novel cudraisoflavone J derivatives
KR102800007B1
Novel mRNA composition and production method for use in Anti-viral and Anti-cancer vaccines
US20220396798A1
